

A Treatment Option for Adult Patients With Newly Diagnosed CP Ph+ CML or Patients With CML Resistant/Intolerant to Prior TKI Therapy



Presented by:

Erinn Hoag Goldman, PhD

Medical Director, Hematology

US Medical Affairs, Pfizer



SUNDAY
12 December
2021
11:30 AM–12:30 PM

Not an official event of the 63rd ASH Annual Meeting and Exposition.
Not sponsored or endorsed by ASH. Not CME-accredited.

